Centre Hospitalier Regional et Universitaire de Lille-ko ikertzaileekin lankidetzan egindako argitalpenak (72)

2024

  1. Slaying the “Troll of Transplantation”—new frontiers in cytomegalovirus management: A report from the CMV International Symposium 2023

    Transplant Infectious Disease, Vol. 26, Núm. 1

2023

  1. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy

    Transplantation and Cellular Therapy, Vol. 29, Núm. 7, pp. 430-437

  2. COVID-19 infection in patients on long-term home parenteral nutrition for chronic intestinal failure

    Clinical Nutrition ESPEN, Vol. 55, pp. 212-220

  3. Economic evaluation of restrictive vs. liberal transfusion strategy following acute myocardial infarction (REALITY): trial-based cost-effectiveness and cost-utility analyses

    European heart journal. Quality of care & clinical outcomes, Vol. 9, Núm. 2, pp. 194-202

  4. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

    Nature Medicine, Vol. 29, Núm. 9, pp. 2259-2267

  5. Pneumocystis jirovecii pneumonia in intensive care units: a multicenter study by ESGCIP and EFISG

    Critical Care, Vol. 27, Núm. 1

2022

  1. Correction to: The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global Study

    The American journal of gastroenterology, Vol. 117, Núm. 5, pp. 818

  2. ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19

    Scientific Data, Vol. 9, Núm. 1

  3. One-Year Major Cardiovascular Events After Restrictive Versus Liberal Blood Transfusion Strategy in Patients With Acute Myocardial Infarction and Anemia: The REALITY Randomized Trial

    Circulation

  4. Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food—A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 77, Núm. 6, pp. 1736-1750

  5. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

    New England Journal of Medicine, Vol. 386, Núm. 7, pp. 629-639

  6. The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global Study

    American Journal of Gastroenterology, Vol. 117, Núm. 2, pp. 301-310

2021

  1. Characteristics of adult patients with chronic intestinal failure due to short bowel syndrome: An international multicenter survey

    Clinical Nutrition ESPEN, Vol. 45, pp. 433-441

  2. Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events among Patients with Acute Myocardial Infarction and Anemia: The REALITY Randomized Clinical Trial

    JAMA - Journal of the American Medical Association, Vol. 325, Núm. 6, pp. 552-560

  3. Factors associated with fears due to COVID-19: A scleroderma patient-centered intervention network (SPIN) COVID-19 cohort study

    Journal of Psychosomatic Research, Vol. 140

  4. Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study

    Journal of Hepatology, Vol. 75, Núm. 5, pp. 1026-1033

  5. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

    The Lancet, Vol. 397, Núm. 10292, pp. 2361-2371

  6. Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis

    Bone Marrow Transplantation, Vol. 56, Núm. 9, pp. 2160-2172

  7. Trimethoprim/sulfamethoxazole for nocardiosis in solid organ transplant recipients: Real-life data from a multicentre retrospective study

    Transplant Infectious Disease, Vol. 23, Núm. 4

2020

  1. First-in-Human Phase I Study of ABBV-838, an Antibody–Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma

    Clinical Cancer Research, Vol. 26, Núm. 10, pp. 2308-2317